Drawing for LIQUISTAL

USPTO serial 86369393

LIQUISTAL

Reviewed by CopyMark Law Group

Reg. 4788812Status 710
Filing date
Status date
Registration date
Aug 11, 2015
Examiner
BUSH, KAREN K
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with LIQUISTAL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Miriam D. Trudell

MIRIAM D. TRUDELL SHERIDAN ROSS P.C.1560 BROADWAY STE 1200DENVER, CO 80202-5145UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for the treatment of the disorder of urogenital organs; Allergy medications; Analgesics; Anti-cancer preparations; Antidepressants; Anti-diabetic pharmaceuticals; Biological preparations for medical purposes; Chemico-pharmaceutical preparations Medical preparations for slimming purposes; Medicinal preparations for stimulating hair growth; Pharmaceutical preparations for treating diabetes; Steroids; Synthetic peptides for pharmaceutical purposes; Thyroid and para-thyroid hormone preparations; Tumor suppressing agentsSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Feb 25, 2022C8..CANCELLED SEC. 8 (6-YR)—
Aug 11, 2020REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Aug 11, 2015R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
May 26, 2015NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 26, 2015PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 6, 2015NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 7, 2015PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
Mar 21, 2015PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Mar 18, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 18, 2015XAECEXAMINER'S AMENDMENT ENTERED—
Mar 18, 2015GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Mar 18, 2015GNEAEXAMINERS AMENDMENT E-MAILED—
Mar 18, 2015CNEAEXAMINERS AMENDMENT -WRITTEN—
Mar 18, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 18, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 11, 2015ALIEASSIGNED TO LIE—
Mar 2, 2015ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Dec 8, 2014GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Dec 8, 2014GNSLLETTER OF SUSPENSION E-MAILED—
Dec 8, 2014CNSLSUSPENSION LETTER WRITTEN—
Dec 3, 2014DOCKASSIGNED TO EXAMINER—
Aug 28, 2014NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 21, 2014NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance